Group 1 - The company plans to use up to RMB 700 million of its idle funds for entrusted wealth management, effective from the board's approval date until the next annual board meeting [1][10][52] - The purpose of the entrusted wealth management is to improve the efficiency of idle funds and increase investment returns for the company and its shareholders [2][9] - The funds for this investment will come from temporarily idle self-owned funds, ensuring that the company's normal operations are not affected [3][4] Group 2 - The investment products will primarily include low-risk, high-security financial products, such as fixed-income products and securities, and will not involve stock investments [4][5] - The board has authorized the management to make investment decisions and sign relevant legal documents, with the finance and funding departments responsible for implementation [5][6] - The company will disclose information regarding the purchase of wealth management products in accordance with the regulations of the Shanghai Stock Exchange [6] Group 3 - The company has also approved changes to certain fundraising projects, including adjustments to investment amounts and project timelines, as well as the addition of new projects [18][19][45] - The project "Mode Animal Mouse R&D Breeding Integrated Base Construction" will have its investment amount reduced from RMB 611.13 million to RMB 430.26 million, and the expected completion date will be extended to April 2030 [21][45] - A new project, "AI-driven Organoid and Animal Disease Model Multi-modal Preclinical Drug Research Platform," with an investment of RMB 200 million, has been introduced to enhance the company's R&D capabilities [24][45]